The Asia Pacific Exosome Diagnostic and Therapeutic Market is expected to witness market growth of 27.1% CAGR during the forecast period (2022-2028).
One of the major factors affecting the exosome diagnostic and therapeutic market demand in the next years is the rising prevalence of chronic disease and the need for screening and diagnosis. One of the major elements driving demand for this industry is exosomes' strong medicinal potential. Another factor driving demand for this market across various regions is the establishment of an explicit method for the investigation of exosome-specific proteins. Furthermore, the rising demand for additional development and research activities, which is further encouraged by government policies around the world, is one of the major factors driving this market's demand upward. The rising adoption of exosomes based on CTC and CTDNA is one of the primary factors impacting the market's growth.
China's rapid socioeconomic development has had a significant impact on its way of life. As a result of these changes in lifestyle, urbanization, and population aging, the risk of cardiovascular disease (CVD) has increased. CVD incidence has been steadily rising, and this upward trend is expected to continue in the coming decade. CVD has become a serious public health concern due to its increasing prevalence. Rising cardiovascular disease cases have necessitated innovative diagnostic and therapeutic techniques.
Since 2006, China's CVD prevalence has been steadily increasing. Stroke, coronary heart disease (CHD), pulmonary heart disease, heart failure (HF), rheumatic heart disease, congenital heart disease, and hypertension affect 13 million, 11 million, 5 million, 4.5 million, 2.5 million, 2 million, and 245 million of the 290 million persons with CVD, respectively. In terms of mortality, CVD is responsible for two out of every five fatalities in China, which is higher than the death rate from cancer or other diseases.
The China market dominated the Asia Pacific Exosome Diagnostic and Therapeutic Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $115.1 million by 2028. The Japan market is experiencing a CAGR of 26.4% during (2022 - 2028). Additionally, The India market is expected to exhibit a CAGR of 27.9% during (2022 - 2028).
Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
One of the major factors affecting the exosome diagnostic and therapeutic market demand in the next years is the rising prevalence of chronic disease and the need for screening and diagnosis. One of the major elements driving demand for this industry is exosomes' strong medicinal potential. Another factor driving demand for this market across various regions is the establishment of an explicit method for the investigation of exosome-specific proteins. Furthermore, the rising demand for additional development and research activities, which is further encouraged by government policies around the world, is one of the major factors driving this market's demand upward. The rising adoption of exosomes based on CTC and CTDNA is one of the primary factors impacting the market's growth.
China's rapid socioeconomic development has had a significant impact on its way of life. As a result of these changes in lifestyle, urbanization, and population aging, the risk of cardiovascular disease (CVD) has increased. CVD incidence has been steadily rising, and this upward trend is expected to continue in the coming decade. CVD has become a serious public health concern due to its increasing prevalence. Rising cardiovascular disease cases have necessitated innovative diagnostic and therapeutic techniques.
Since 2006, China's CVD prevalence has been steadily increasing. Stroke, coronary heart disease (CHD), pulmonary heart disease, heart failure (HF), rheumatic heart disease, congenital heart disease, and hypertension affect 13 million, 11 million, 5 million, 4.5 million, 2.5 million, 2 million, and 245 million of the 290 million persons with CVD, respectively. In terms of mortality, CVD is responsible for two out of every five fatalities in China, which is higher than the death rate from cancer or other diseases.
The China market dominated the Asia Pacific Exosome Diagnostic and Therapeutic Market by Country in 2021, and is expected to continue to be a dominant market till 2028; thereby, achieving a market value of $115.1 million by 2028. The Japan market is experiencing a CAGR of 26.4% during (2022 - 2028). Additionally, The India market is expected to exhibit a CAGR of 27.9% during (2022 - 2028).
Based on Application, the market is segmented into Diagnostic and Therapeutic. Based on Product, the market is segmented into Reagent, Instrument, and Software. Based on End User, the market is segmented into Cancer Institute, Hospital, Diagnostic Center, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Qiagen N.V., Thermo Fisher Scientific, Inc., Aethlon Medical, Inc., Capricor Therapeutics, Inc., Malvern Panalytical Ltd., NanoSomix, Inc., System Biosciences, LLC, and NX Pharmagen, Inc.
Scope of the Study
Market Segments Covered in the Report:
By Application
- Diagnostic
- Therapeutic
By Product
- Reagent
- Instrument
- Software
By End User
- Cancer Institute
- Hospital
- Diagnostic Center
- Others
By Country
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
Key Market Players
List of Companies Profiled in the Report:
- Bio-Techne Corporation
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Aethlon Medical, Inc.
- Capricor Therapeutics, Inc.
- Malvern Panalytical Ltd.
- NanoSomix, Inc.
- System Biosciences, LLC
- NX Pharmagen, Inc.
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Asia Pacific Exosome Diagnostic and Therapeutic Market by Application
Chapter 5. Asia Pacific Exosome Diagnostic and Therapeutic Market by Product
Chapter 6. Asia Pacific Exosome Diagnostic and Therapeutic Market by End User
Chapter 7. Asia Pacific Exosome Diagnostic and Therapeutic Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bio-Techne Corporation
- Qiagen N.V.
- Thermo Fisher Scientific, Inc.
- Aethlon Medical, Inc.
- Capricor Therapeutics, Inc.
- Malvern Panalytical Ltd.
- NanoSomix, Inc.
- System Biosciences, LLC
- NX Pharmagen, Inc.
Methodology
LOADING...
